Positive news but can I play devils advocate for a moment. There were a number of positive and very robust results that came out of the phase 2 trials that did not play out in BoM. Is there not a similar risk of some of these big HR numbers from BOM meeting a similar fate in BoM2 or should those statistical CI percentages hold up?